Ican-prevent: MD anderson international cancer prevention clinical trial consortium

Active Cooperative Agreement Awarded Last action

Award ID
UG1CA242609
Recipient
Awarding agency
Obligated
$18,109,393

Award facts

Assistance listing
93.399 Cancer Control
Completion date 61% complete
Originally
Place of performance
Houston, TX 77030, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $733,978
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $1,627,502
Amendment $1,627,502
Amendment $1,627,502
Amendment $1,627,502
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $1,321,621
Amendment $1,321,621
Amendment $0
Amendment $1,363,358
Amendment $1,363,358
Amendment $911,328
Amendment $1,822,363
Amendment $0
Amendment $1,814,563
Amendment $0
Original award $947,195
Show all 26

Subawards

Subrecipient Amount Awarded
Dana-Farber Cancer Institute, Inc. Months 1-6 study start up tasks, including submission of CIRB-approved protocol to local IRB and obtaining approval, establishing work-flow for image transfer… $60,180
Dana-Farber Cancer Institute, Inc. The primary objective of this study is to evaluate if the combination of trivalent adenovirus-5 (Tri-Ad5) vaccines and IL-15 superagonist N-803 reduces the… $23,777
Dana-Farber Cancer Institute, Inc. submission of CIRB-approved protocol to local IRB and obtaining approval, establishing work-flow for image transfer of mammorgrams to TRIAD within 4 days,… $19,293
Dana-Farber Cancer Institute, Inc. Months 1-6 study start up tasks, including submission of CIRB-approved protocol to local IRB and obtaining approval, establishing work-flow for image transfer… $111,620
The Institute For Cancer Research The primary objective of this study is to evaluate if the combination of trivalent adenovirus-5 (Tri-Ad5) vaccines and IL-15 subperagonist N-803 reduces the… $12,511
Fox Chase Cancer Center A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/BRACHYURY) Vaccines (TRI-AD5) and IL-15 Superagonist N-803 in Lynch… $75,500
Ente Ospedaliero Ospedali Galliera DI Genova The primary interim objective will be to assess the safety of the experimental intervention based on the frequency of occurrence of a Dose Limiting Toxicity… $241,994
Dana-Farber Cancer Institute, Inc. Dana-Farber Cancer Institute Serving as the Site PI/Co-Investigator, Dr. Ramona Lim and the Dana-Farber Cancer Institute will participate in a multicenter… $170,750
Beckman Research Institute Of The City Of Hope DCP Protocol Number: INT21-05-01 Title of Study: A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/BRACHYURY) Vaccines… $12,250
Beckman Research Institute Of The City Of Hope $14,283
Dana-Farber Cancer Institute, Inc. Dana-Farber Cancer Institute Serving as the Site PI/Co-Investigator, Dr. Ramona Lim and the Dana-Farber Cancer Institute will participate in a multicenter… $133,549
Beckman Research Institute Of The City Of Hope Subrecipient will participate in the design and conduct of a Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce… $5,405
Beckman Research Institute Of The City Of Hope $5,750
Dana-Farber Cancer Institute, Inc. $5,800
University Of Kansas Center For Research Inc. $13,150
Dana-Farber Cancer Institute, Inc. $3,222
University Of Kansas Medical Center Research Institute, Inc. $12,732
The Institute For Cancer Research DCP Protocol Number: INT21-05-01 Title of Study: A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/BRACHYURY) Vaccines… $33,198
Centro Comprensivo De Cancer De La Universidad De Puerto Rico The study team will be responsible for recruitment and retention of study participants, performance of study evaluations and procedures, collection of study… $24,500
University Of Puerto Rico Medical Sciences Campus Subrecipient will participate in the design and conduct of a Phase Ib/II Clinical Trial of Nous-209 (vaccine) for Recurrent Neoantigen Immunogenicity and Cancer… $9,706
Beckman Research Institute Of The City Of Hope Primary Objectives a) To evaluate the safety and tolerability of GAd20-209-FSPs (1 prime) and MVA-209-FSPs (1 boost) vaccination when administered as a single… $1,760
Beckman Research Institute Of The City Of Hope a) To evaluate the safety and tolerability of GAd20-209-FSPs (1 prime) and MVA-209-FSPs (1 boost) vaccination when administered as a single agent… $28,300
The Institute For Cancer Research To assess the effect of Nous-209 vaccination on T cell immune profile and T cell receptor (TCR) repertoire in the peripheral blood of participants with LS. b)… $122,996
University Of Puerto Rico To evaluate the safety and tolerability of GAd20-209-FSPs (1 prime) and MVA-209-FSPs (1 boost) vaccination when administered as a single agent (monotherapy)… $61,288
The Institute For Cancer Research To assess the effect of Nous-209 vaccination on T cell immune profile and T cell receptor (TCR) repertoire in the peripheral blood of participants with LS. b)… $51,341
Dana-Farber Cancer Institute, Inc. A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/BRACHYURY) Vaccines (TRI-AD5) and IL-15 Superagonist N-803 in Lynch… $228,275
Dana-Farber Cancer Institute, Inc. To evaluate the effect of treatment with OCA versus treatment with placebo on duodenal polyp burden (sum of polyp diameters) in participants with FAP. $65,213
Show all 27

Quick answers

Who received award UG1CA242609?

UG1CA242609 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on August 15, 2019.

How much is award UG1CA242609 worth?

$18,109,393 has been obligated on UG1CA242609.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login